Title: David Rex Musgrave: Innovator in Prostate Cancer Diagnosis
Introduction: David Rex Musgrave is an inventor based in Hamilton, New Zealand. He is currently associated with Caldera Health Limited, where he focuses on advancements in medical diagnostics. Although he has not yet been granted any patents, his work is significant in the field of cancer diagnosis.
Latest Patent Applications: David Rex Musgrave's latest patent application is titled "Gene Expression Profiling for the Diagnosis of Prostate Cancer." This application outlines methods for diagnosing the presence of disorders, such as prostate cancer, in subjects. The methods include detecting the relative frequency of expression of RNA biomarkers in biological samples obtained from subjects, utilizing next-generation sequencing (NGS) technology. The application emphasizes comparing the relative levels of expression with predetermined threshold levels. Levels of expression of at least two RNA biomarkers that exceed or fall below these thresholds are indicative of the presence of prostate cancer. Additionally, the application provides a method for preparing a reference standard to quantify the relative frequency of expression of RNA biomarkers in samples from subjects with prostate cancer lesions using NGS technology.
Conclusion: David Rex Musgrave is making strides in the field of medical diagnostics, particularly in the early detection of prostate cancer through innovative methods. His contributions, although not yet reflected in granted patents, hold promise for future advancements in healthcare.